Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

661
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
661
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

879
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
879
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

773
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
773

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HSR26-212: Association Between Insurance Type and Quality of Life Changes in Cancer Patients Receiving Radiotherapy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

HSR26-212: Association Between Insurance Type and Quality of Life Changes in Cancer Patients Receiving Radiotherapy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

ISDE guidelines on the management of cT2N0 esophageal cancer.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

Tipping the Scales for Bladder Cancer: Weighing Differences in Quality of Life After Cystectomy Versus Trimodality Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients.

The oncologist·2024
Same author

Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer.

Advances in radiation oncology·2024

Related Experiment Video

Updated: Apr 10, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.5K

Radiotherapy Issues After Neoadjuvant Chemotherapy.

Kimberley S Mak1, Jay R Harris2

  • 1Harvard Radiation Oncology Program, Boston, MA (KSM); Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (JRH).

Journal of the National Cancer Institute. Monographs
|June 12, 2015
PubMed
Summary

Neoadjuvant chemotherapy (NCT) enables breast-conserving therapy (BCT) for more patients. Radiotherapy (RT) use after NCT and surgery is selective, guided by residual disease and patient stage.

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Related Experiment Videos

Last Updated: Apr 10, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.5K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Radiotherapy (RT) is a standard treatment following neoadjuvant chemotherapy (NCT) and breast-conserving surgery (BCT).
  • NCT facilitates pathologic down-staging, increasing eligibility for BCT over mastectomy, even in select Stage III patients with good response.
  • Achieving clear surgical margins is crucial for all BCT candidates.

Purpose of the Study:

  • To review the established and evolving indications for radiotherapy following neoadjuvant chemotherapy in breast cancer.
  • To clarify the role of postmastectomy radiotherapy (PMRT) based on patient stage and response to NCT.
  • To highlight ongoing research into the use of axillary radiotherapy in the context of NCT.

Main Methods:

  • Review of current clinical practice and guidelines for RT use post-NCT.
  • Analysis of retrospective data and key clinical trials (NSABP B-18, B-27) informing RT recommendations.
  • Identification of patient subgroups with intermediate risk based on residual disease after NCT.

Main Results:

  • PMRT is indicated for locally advanced breast cancer and residual nodal involvement post-NCT.
  • Stage I-II patients achieving a pathologic complete response after NCT do not require PMRT.
  • Patients with residual breast involvement but no nodal involvement represent an intermediate-risk group for RT decisions.

Conclusions:

  • RT indications post-NCT are becoming more refined, balancing treatment benefits with patient outcomes.
  • Selective use of RT, particularly PMRT, is guided by pathologic response and staging after NCT.
  • The role of axillary RT following NCT is an active area of investigation in ongoing trials.